ZS Associates

1 month ago | biopharmadive.com | ZS Associates |Ben Fidler

A young man with Duchenne muscular dystrophy has died following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the company said Tuesday. In a short statement, Sarepta said the patient suffered acute liver failure after receiving Elevidys, the only approved gene therapy for the disease. Liver damage is a known risk of treatment with Elevidys as well as other gene therapies that are built around a type of modified virus.

Feb 16, 2024 | techgig.com | ZS Associates

Please verify your internet connection and retry The Browser we detected is unsupported and may result in unexpected behaviour. Please select an updated version for best experience.

Aug 2, 2023 | pharmexec.com | ZS Associates

By ZS Associates Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS's approach for Patient Outcomes Impact (POI).

Aug 2, 2023 | pharmexec.com | ZS Associates

Patient centricity is an imperative focus for the advancement of life sciences businesses, and Sharon Suchotliff from ZS delves into this topic by sharing her keen insights.

Mar 22, 2023 | appliedclinicaltrialsonline.com | ZS Associates

Using Clinical Trial Sites' Input to Select the Right Capabilities when Decentralizing Clinical TrialsPublished on: March 22, 2023This paper analyses the responses from more than 800 US-based clinical trial sites to understand their decentralized clinical trial capabilities and perceptions